Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA)Zacks Investment Research • 02/14/25
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatePRNewsWire • 02/13/25
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLCPRNewsWire • 02/13/25
Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study ComingSeeking Alpha • 02/10/25
All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to BuyZacks Investment Research • 02/10/25
IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial OfficerPRNewsWire • 02/10/25
IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations EventsPRNewsWire • 01/27/25
IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate GuidancePRNewsWire • 01/12/25
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid TumorsPRNewsWire • 12/29/24
IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal MelanomaPRNewsWire • 12/17/24
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung CancersPRNewsWire • 12/16/24
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial CancerPRNewsWire • 12/10/24
IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 InhibitorPRNewsWire • 12/09/24
Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge CashSeeking Alpha • 12/04/24
IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations EventsPRNewsWire • 12/02/24
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D DayPRNewsWire • 11/12/24
IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with BiocytogenPRNewsWire • 11/11/24
Biocytogen Announces IDEAYA's Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option ExerciseBusiness Wire • 11/11/24
Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should KnowZacks Investment Research • 11/07/24
IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business UpdatePRNewsWire • 11/04/24
Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to DeclineZacks Investment Research • 10/29/24
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid TumorsPRNewsWire • 10/28/24